Efficacy of Bacillus clausii and Saccharomyces boulardii in Treatment of Acute Rotaviral Diarrhea in Pediatric Patients
Abstract
Diarrhea disease is considered as major health problem in developing countries. Rotavirus is the most common identifiable viral cause of diarrhea in all children and belongs to Reoviridae family. Rotavirus infection occasionally leads to severe dehydration in infants and children. The objective of the study is to assess the efficacy of Bacillus clausii and Saccharomyces boulardii on the treatment of rotaviral diarrhea, and also to assess its effect on vomiting and fever in pediatric patients. This study conducted at Rainbow Children’s Hospital, Hyderabad, India, from January 2016 until June 2016 and adopts prospective observational parallel study design. From 104 patients enrolled, 80 fulfilled inclusion criteria and 24 were excluded from the study. Patients were divided into two groups based on the treatment. Group I patients were treated with Bacillus clausii and Group II patients were treated with Saccharomyces boulardii. Total mean duration of diarrhea was significantly shorter in Group II (S. boulardii) in comparison with Group I (B. clausii). S. boulardii significantly (p≤0.005) decreased the duration of diarrhea which is 25.2 hours over B. clausii. Both probiotic preparations were equal in efficacy on treating the vomiting and fever (p≥0.005). S. boulardii and B. clausii were well accepted and tolerated by the children and there were no reports of any adverse effects during the study period.
Keywords: Bacillus clausii, probiotics, rotaviral diarrhea, Saccharomyces boulardii
Efektivitas Bacillus clausii dan Saccharomyces boulardii dalam Pengobatan Diare Akut akibat Rotavirus pada Pasien Anak
Abstrak
Penyakit diare merupakan salah satu masalah kesehatan yang paling utama di negara-negara berkembang. Rotavirus merupakan virus famili Reoviridae yang umumnya menjadi penyebab diare pada anak. Infeksi rotavirus dapat menyebabkan dehidrasi berat pada bayi dan anak-anak. Tujuan penelitian ini adalah untuk mengukur efektivitas Bacillus clausii dan Saccharomyces boulardii pada pengobatan diare rotavirus dan juga untuk menilai pengaruhnya terhadap muntah dan demam pada pasien anak-anak. Studi ini dilakukan di Rumah Sakit Rainbow Children, Hyderabad, India, pada bulan Januari–Juni 2016 dan menggunakan desain penelitian paralel observasional prospektif. Dari 104 pasien yang terdaftar, sebanyak 80 pasien memenuhi kriteria inklusi dan 24 pasien masuk ke dalam kriteria eksklusi. Pasien dibagi ke dalam dua kelompok berdasarkan pengobatan. Kelompok I merupakan pasien yang diberikan Bacillus clausii dan Kelompok II merupakan pasien yang diberikan Saccharomyces boulardii. Durasi rata-rata diare spada Kelompok II secara signifikan lebih pendek dibandingkan Kelompok I. S. boulardii secara signifikan menurunkan durasi diare (p≤0.005) yaitu 25,2 jam lebih cepat dari B. clausii. Kedua preparat probiotik sama efektifnya dalam mengobati muntah dan demam (p≥0.005). S. boulardii dan B. clausii dapat diterima dengan baik dan ditoleransi oleh anak-anak, serta tidak ada laporan tentang efek samping selama masa studi.
Kata kunci: Bacillus clausii, diare rotavirus, probiotik, Saccharomyces boulardii
Keywords
Full Text:
PDFReferences
World Health Organization. Definitions of diarrhea [Accessed on: 1st June 2016] Available at: http://www.who.int/mediace ntre/factsheets/fs330/en/
Trivedi AV, Ram RV, Patel KB. Epidemic investigation of an acute gastroenteritis outbreak in daslana village of Ahmedabad, Gujarat. Natl J Med Res. 2013;3(3):267–9.
Bernstein DI. The changing epidemiology of rotavirus gastroenteritis. J Pediatr Infect Dis. 2009;28(3):49. doi: 10.1097/INF.0b013e3181967bda
John BM, Devgan A, Mitra B. Prevalence of rotavirus infection in children below two years presenting with diarrhoea. Med J Armed Forces India. 2014;70(2):116–9. doi: 10.1016/j.mjafi.2014.02.008
Wilhelmi I, Roman E, Fauquier AS. Virus causing gastroenteritis. Clin Microbial Infect. 2009;9(4):247–62. doi: 10.1046/j.1469-0691.2003.00560.x
Surendran S. Rotavirus infection: Molecular changes and pathophysiology. EXCLI J. 2008;7:154–62.
Anukam KC. Probiotics: 100 years (1907–2007) after Elie Metchnikoff’s observation: Communicating current research and educational topics and trends in applied microbiology. FORMATEX. 2007:466–74.
Guo M. Prebiotics and probiotics. J Prob Health. 2015;3(2):120. doi: 10.4172/2329 -8901.1000e120
Gogineni VK, Morrow LE, Malesker MA. Probiotics: Mechanisms of action and clinical applications. J Prob Health. 2013;1(1):1–11. doi: 10.4172/2329-8901.1000101
Chauhan S, Chauhan R, Vinod S. Role of Lactobacillus rhamnosus GG and Saccharomyces boulardii in antibiotic associated diarrhea. J Prob Health. 2015;3(2):1–5. doi: 10.4172/2329-8901.1000131
Htwe K, Yee S, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: A randomized controlled study. Am J Trop Med Hyg. 2008;78(2):214–6.
Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Shekhani MS, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhea. World J Gastroenterol. 2006; 12(28):4557–60. doi: 10.3748/wjg.v12.i28.4557
Ozkan TB, Sahin E, Budak F. Effect of saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune response. J Intern Med Res. 2007;35(2):201–12. doi: 10.1177/147323000703500204
Villarruel G, Rubio DM. Saccharomyces boulardii in acute childhood diarrhoea: A randomized, placebo-controlled study. Acta Paediatr. 2007;96(4):538–41. doi: 10. 1111/j.1651-2227.2007.00191.x
Candy DCA. Rotavirus infection: A systemic illness?. PLoS Med. 2007;4(4):e117. doi: 10.1371/journal.pmed.0040117
Vandenplas Y, Salvatore S, Vieira MC, Devreker T, Hauser B. Probiotics in infectious diarrhoea in children: Are they indicated?. Eur J Pediatr. 2007;166(12):1211–8. doi: 10.1007/s00431-007-0497-9
Mohammed AA, Aminu M, Ado SA, Jatau ED, Esona MD. Prevalence of rotavirus among children under five years of age with diarrhea in Kaduna State, Nigeria. Niger J Paediatr. 2016;43(4):264 –8. doi: 10.4314/njp.v43i4.6
Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 2006;131 (6):1812–25. doi: 10.1053/j.gastro.2006.10.001
Kolader M, Vinh H, Tuyet PTN, Thompson C, Wolbers M, Merson L, et al. An oral preparation of Lactobacillus acidophilus for the treatment of uncomplicated acute watery diarrhoea in Vietnamese children: Study protocol for a multicentre, randomised, placebo controlled trial. Trials. 2013;14(27):1–9. doi: 10.1186/1745-6215-14-27
Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: Updates and perspectives. Dig Dis Sciences. 2009;54(1):15–8. doi: 10.1007/s10620-008-0322-y
Lahiri K, Souza JD, Gahlowt P. Beneficial role of probiotic in acute childhood diarrhoea. J Harmoniz Res Med Hlth Sci. 2015;2(2):26–30.
Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;10(11):CD003048. doi: 10.1002/14651858.CD003048.pub3
Johnston BC, Supina AL, Ospina M, Vohra S. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2007;18(1): CD004827. doi: 10.1002/14651858.CD004827.pub2
Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D. Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25(8):871–81. doi: 10.1111/j.1 365-2036.2007.03282.x
Kelesidis T. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv in Gastroenterol. 2012;5(2):111–25. doi: 10.1177/1756283X11428502
DOI: https://doi.org/10.15416/ijcp.2017.6.2.91
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
